Gossamer Bio Inc

-0.06 (-4.58%)


Draw Mode:

Volume 397,276
Bid Price 1.25
Ask Price 1.26
News -
Day High 1.31


52 Week Range


Day Low 1.24
Company Name Stock Ticker Symbol Market Type
Gossamer Bio Inc GOSS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -4.58% 1.25 12:52:08
Open Price Low Price High Price Close Price Prev Close
1.28 1.24 1.31 1.31
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,440 397,276 $ 1.27 $ 504,856 - 0.9103 - 15.195
Last Trade Time Type Quantity Stock Price Currency
12:52:08 22 $ 1.2511 USD

Gossamer Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 119.31M 95.44M 74.25M $ - $ - -0.52 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 925.92k 5.20%

more financials information »

Gossamer Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GOSS Message Board. Create One! See More Posts on GOSS Message Board See More Message Board Posts

Historical GOSS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.311.3851.191.281,568,213-0.06-4.58%
1 Month1.361.621.091.341,933,501-0.11-8.09%
3 Months1.291.620.91031.162,972,375-0.04-3.1%
6 Months9.009.550.91031.924,555,897-7.75-86.11%
1 Year7.3315.1950.91034.082,985,331-6.08-82.95%
3 Years12.6215.870.91035.911,423,613-11.37-90.1%
5 Years18.7227.14970.91037.221,120,769-17.47-93.32%

Gossamer Bio Description

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.